{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:11:04Z","timestamp":1788315064768,"version":"build-2803163510"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41380-025-03081-2","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T07:59:55Z","timestamp":1750492795000},"page":"4899-4909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Advance and Prospect of Positron Emission Tomography in Alzheimer\u2019s disease research"],"prefix":"10.1038","volume":"30","author":[{"given":"Yulin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3446-4183","authenticated-orcid":false,"given":"Ping","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"3081_CR1","doi-asserted-by":"crossref","unstructured":"Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer\u2019s disease. Neurologia. 2000;15.","DOI":"10.1016\/S0197-4580(00)82678-0"},{"key":"3081_CR2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/jnnp.2005.085332","volume":"77","author":"F Portet","year":"2006","unstructured":"Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer\u2019s Disease. J Neurol Neurosurg Psychiatry. 2006;77:714\u201318.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3081_CR3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet"},{"key":"3081_CR4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"3081_CR5","unstructured":"Alzheimer\u2019s Disease International. World Alzheimer Report 2018. The state of the art of dementia research: new frontiers. September, 2018."},{"key":"3081_CR6","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","volume":"5","author":"L Jia","year":"2020","unstructured":"Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5:e661\u2013e71.","journal-title":"Lancet Public Health"},{"key":"3081_CR7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/alz.12684","volume":"19","author":"J V\u00f6glein","year":"2023","unstructured":"V\u00f6glein J, Franzmeier N, Morris JC, Dieterich M, McDade E, Simons M, et al. Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2023;19:632\u201345.","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association."},{"key":"3081_CR8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13195-019-0474-3","volume":"11","author":"EE De Roeck","year":"2019","unstructured":"De Roeck EE, De Deyn PP, Dierckx E, Engelborghs S. Brief cognitive screening instruments for early detection of Alzheimer\u2019s disease: a systematic review. Alzheimers Res Ther. 2019;11:21.","journal-title":"Alzheimers Res Ther"},{"key":"3081_CR9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med. 2018;284:643\u201363.","journal-title":"J Intern Med"},{"key":"3081_CR10","doi-asserted-by":"crossref","unstructured":"Klepl D, He F, Wu M, Marco MD, Blackburn DJ, Sarrigiannis PG Characterising Alzheimer\u2019s Disease With EEG-Based Energy Landscape Analysis. IEEE J Biomed Health Inform. 2022;26.","DOI":"10.1109\/JBHI.2021.3105397"},{"key":"3081_CR11","doi-asserted-by":"crossref","unstructured":"van Oostveen WM, de Lange ECM Imaging Techniques in Alzheimer\u2019s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22042110"},{"key":"3081_CR12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00259-019-04640-w","volume":"47","author":"A Kas","year":"2020","unstructured":"Kas A, Migliaccio R, Tavitian B. A future for PET imaging in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020;47:231\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3081_CR13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/461895a","volume":"461","author":"L Mucke","year":"2009","unstructured":"Mucke L. Neuroscience: Alzheimer\u2019s disease. Nature. 2009;461:895\u201397.","journal-title":"Nature"},{"key":"3081_CR14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jalz.2005.09.001","volume":"1","author":"ZS Khachaturian","year":"2005","unstructured":"Khachaturian ZS. Diagnosis of Alzheimer\u2019s disease: two decades of progress. Alzheimer\u2019s & Dementia : the Journal of the Alzheimer\u2019s Association. 2005;1:93\u20138.","journal-title":"Alzheimer\u2019s & Dementia : the Journal of the Alzheimer\u2019s Association"},{"key":"3081_CR15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol. 2017;16:661\u201376.","journal-title":"Lancet Neurol"},{"key":"3081_CR16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ. In vivo staging of regional amyloid deposition. Neurology. 2017;89:2031\u201338.","journal-title":"Neurology"},{"key":"3081_CR17","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Sch\u00f6ll M, Strandberg O, et al. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2018;320:1151\u201362.","journal-title":"JAMA"},{"key":"3081_CR18","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.metabol.2014.10.034","volume":"64","author":"R Wurtman","year":"2015","unstructured":"Wurtman R. Biomarkers in the diagnosis and management of Alzheimer\u2019s disease. Metabolism. 2015;64:S47\u2013S50.","journal-title":"Metabolism"},{"key":"3081_CR19","doi-asserted-by":"crossref","first-page":"16247","DOI":"10.1523\/JNEUROSCI.2027-14.2014","volume":"34","author":"ME Murray","year":"2014","unstructured":"Murray ME, Przybelski SA, Lesnick TG, Liesinger AM, Spychalla A, Zhang B, et al. Early Alzheimer\u2019s disease neuropathology detected by proton MR spectroscopy. J Neurosci. 2014;34:16247\u201355.","journal-title":"J Neurosci"},{"key":"3081_CR20","doi-asserted-by":"crossref","first-page":"e043307","DOI":"10.1002\/alz.043307","volume":"16","author":"R Sala-Llonch","year":"2020","unstructured":"Sala-Llonch R, Contador J, P\u00e9rez-Millan A, Falg\u00e0s N, Ruiz-Peris M, Tort-Merino A, et al. Functional network alterations in early-onset Alzheimer\u2019s disease studied with resting-state fMRI. Alzheimer\u2019s & Dementia. 2020;16:e043307.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"3081_CR21","doi-asserted-by":"crossref","DOI":"10.1002\/alz.093844","volume":"20","author":"R Lattmann","year":"2024","unstructured":"Lattmann R, Vockert N, Wesenberg J, Yakupov R, Suksangkharn Y, Sch\u00fctze H, et al. Abnormalities in task-fMRI activation are related to disease progression towards Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2024;20:e093844.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"3081_CR22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3389\/fnins.2019.00738","volume":"13","author":"W Zheng","year":"2019","unstructured":"Zheng W, Cui B, Han Y, Song H, Li K, He Y, et al. Disrupted Regional Cerebral Blood Flow, Functional Activity and Connectivity in Alzheimer\u2019s Disease: A Combined ASL Perfusion and Resting State fMRI Study. Front Neurosci. 2019;13:738.","journal-title":"Front Neurosci"},{"key":"3081_CR23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3233\/JAD-2012-112168","volume":"30","author":"A Schmidt","year":"2012","unstructured":"Schmidt A, Pahnke J. Efficient near-infrared in vivo imaging of amyoid-\u03b2 deposits in Alzheimer\u2019s disease mouse models. J Alzheimers Dis. 2012;30:651\u201364.","journal-title":"J Alzheimers Dis"},{"key":"3081_CR24","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3233\/JAD-181242","volume":"68","author":"CM Roe","year":"2019","unstructured":"Roe CM, Stout SH, Rajasekar G, Ances BM, Jones JM, Head D, et al. A 2.5-Year Longitudinal Assessment of Naturalistic Driving in Preclinical Alzheimer\u2019s Disease. J Alzheimers Dis. 2019;68:1625\u201333.","journal-title":"J Alzheimers Dis"},{"key":"3081_CR25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/WCO.0000000000000570","volume":"31","author":"JL Whitwell","year":"2018","unstructured":"Whitwell JL. Alzheimer\u2019s disease neuroimaging. Curr Opin Neurol. 2018;31:396\u2013404.","journal-title":"Curr Opin Neurol"},{"key":"3081_CR26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.acra.2013.11.002","volume":"21","author":"S Hess","year":"2014","unstructured":"Hess S, Blomberg BA, Zhu HJ, H\u00f8ilund-Carlsen PF, Alavi A. The pivotal role of FDG-PET\/CT in modern medicine. Acad Radiol. 2014;21:232\u201349.","journal-title":"Acad Radiol"},{"key":"3081_CR27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","volume":"32","author":"L Mosconi","year":"2005","unstructured":"Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer\u2019s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486\u2013510.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3081_CR28","doi-asserted-by":"crossref","unstructured":"Marcus C, Mena E, Subramaniam RM Brain PET in the diagnosis of Alzheimer\u2019s disease. Clin Nucl Med. 2014;39.","DOI":"10.1097\/RLU.0000000000000547"},{"key":"3081_CR29","doi-asserted-by":"crossref","unstructured":"Weiner MW, Aisen PS, Jack CR, Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer\u2019s disease neuroimaging initiative: progress report and future plans. Alzheimer\u2019s & Dementia : the Journal of the Alzheimer\u2019s Association. 2010;6.","DOI":"10.1016\/j.jalz.2010.03.007"},{"key":"3081_CR30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13195-019-0512-1","volume":"11","author":"Y-N Ou","year":"2019","unstructured":"Ou Y-N, Xu W, Li J-Q, Guo Y, Cui M, Chen K-L, et al. FDG-PET as an independent biomarker for Alzheimer\u2019s biological diagnosis: a longitudinal study. Alzheimers Res Ther. 2019;11:57.","journal-title":"Alzheimers Res Ther"},{"key":"3081_CR31","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/brain\/awf097","volume":"125","author":"B Desgranges","year":"2002","unstructured":"Desgranges B, Baron J-C, Lalev\u00e9e C, Giffard B, Viader F, de La Sayette V, et al. The neural substrates of episodic memory impairment in Alzheimer\u2019s disease as revealed by FDG-PET: relationship to degree of deterioration. Brain. 2002;125:1116\u201324.","journal-title":"Brain"},{"key":"3081_CR32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00415-005-0685-3","volume":"252","author":"G Kalpouzos","year":"2005","unstructured":"Kalpouzos G, Eustache F, de la Sayette V, Viader F, Ch\u00e9telat G, Desgranges B. Working memory and FDG-PET dissociate early and late onset Alzheimer disease patients. J Neurol. 2005;252:548\u201358.","journal-title":"J Neurol"},{"key":"3081_CR33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116645","volume":"410","author":"L Gjerum","year":"2020","unstructured":"Gjerum L, Frederiksen KS, Henriksen OM, Law I, Anderberg L, Andersen BB, et al. A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer\u2019s disease. J Neurol Sci. 2020;410:116645.","journal-title":"J Neurol Sci"},{"key":"3081_CR34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.semnuclmed.2021.01.002","volume":"51","author":"S Minoshima","year":"2021","unstructured":"Minoshima S, Mosci K, Cross D, Thientunyakit T. Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer\u2019s Disease and Other Types of Dementing Disorders. Semin Nucl Med. 2021;51:230\u201340.","journal-title":"Semin Nucl Med"},{"key":"3081_CR35","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00259-018-4032-1","volume":"45","author":"A Drzezga","year":"2018","unstructured":"Drzezga A, Altomare D, Festari C, Arbizu J, Orini S, Herholz K, et al. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2018;45:1487\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3081_CR36","first-page":"e106","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimer\u2019s & Dementia : the Journal of the Alzheimer\u2019s Association. 2013;9:e106\u2013e09.","journal-title":"Alzheimer\u2019s & Dementia : the Journal of the Alzheimer\u2019s Association."},{"key":"3081_CR37","doi-asserted-by":"crossref","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2015;11.","DOI":"10.1016\/j.jalz.2014.07.003"},{"key":"3081_CR38","doi-asserted-by":"crossref","unstructured":"Villemagne VL, Ch\u00e9telat G Neuroimaging biomarkers in Alzheimer\u2019s disease and other dementias. Ageing Res Rev. 2016;30.","DOI":"10.1016\/j.arr.2016.01.004"},{"key":"3081_CR39","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2967\/jnumed.116.184481","volume":"58","author":"J Ottoy","year":"2017","unstructured":"Ottoy J, Verhaeghe J, Niemantsverdriet E, Wyffels L, Somers C, De Roeck E, et al. Validation of the Semiquantitative Static SUVR Method for 18F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function. J Nucl Med. 2017;58:1483\u201389.","journal-title":"J Nucl Med"},{"key":"3081_CR40","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1093\/brain\/awl281","volume":"129","author":"WE Klunk","year":"2006","unstructured":"Klunk WE, Mathis CA, Price JC, Lopresti BJ, DeKosky ST. Two-year follow-up of amyloid deposition in patients with Alzheimer\u2019s disease. Brain. 2006;129:2805\u201307.","journal-title":"Brain"},{"key":"3081_CR41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.21164","volume":"62","author":"KA Johnson","year":"2007","unstructured":"Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229\u201334.","journal-title":"Ann Neurol"},{"key":"3081_CR42","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/mds.25048","volume":"27","author":"SN Gomperts","year":"2012","unstructured":"Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord. 2012;27:965\u201373.","journal-title":"Mov Disord"},{"key":"3081_CR43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"3081_CR44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275\u201383.","journal-title":"JAMA"},{"key":"3081_CR45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 2012;11:669\u201378.","journal-title":"Lancet Neurol"},{"key":"3081_CR46","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3233\/JAD-160760","volume":"55","author":"A-M Waldron","year":"2017","unstructured":"Waldron A-M, Wyffels L, Verhaeghe J, Richardson JC, Schmidt M, Stroobants S, et al. Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model. J Alzheimers Dis. 2017;55:1537\u201348.","journal-title":"J Alzheimers Dis"},{"key":"3081_CR47","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1445-5994.2006.01153.x","volume":"36","author":"DR Williams","year":"2006","unstructured":"Williams DR. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J. 2006;36:652\u201360.","journal-title":"Intern Med J"},{"key":"3081_CR48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-017-0162-3","volume":"12","author":"L Saint-Aubert","year":"2017","unstructured":"Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12:19.","journal-title":"Mol Neurodegener"},{"key":"3081_CR49","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/alz.12356","volume":"17","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Hansson O. Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia : the Journal of the Alzheimer\u2019s Association. 2021;17:1998\u20132008.","journal-title":"Alzheimer\u2019s & Dementia : the Journal of the Alzheimer\u2019s Association"},{"key":"3081_CR50","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022;21:726\u201334.","journal-title":"Lancet Neurol"},{"key":"3081_CR51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"3081_CR52","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2016.5755","volume":"74","author":"C Xia","year":"2017","unstructured":"Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, et al. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA Neurol. 2017;74:427\u201336.","journal-title":"JAMA Neurol"},{"key":"3081_CR53","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3233\/JAD-170740","volume":"62","author":"KA Tetzloff","year":"2018","unstructured":"Tetzloff KA, Graff-Radford J, Martin PR, Tosakulwong N, Machulda MM, Duffy JR, et al. Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer\u2019s Disease. J Alzheimers Dis. 2018;62:1713\u201324.","journal-title":"J Alzheimers Dis"},{"key":"3081_CR54","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/jnnp-2020-325497","volume":"92","author":"E Singleton","year":"2021","unstructured":"Singleton E, Hansson O, Pijnenburg YAL, La Joie R, Mantyh WG, Tideman P, et al. Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2021;92:872\u201380.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3081_CR55","volume":"12","author":"I Sonni","year":"2020","unstructured":"Sonni I, Lesman Segev OH, Baker SL, Iaccarino L, Korman D, Rabinovici GD, et al. Evaluation of a visual interpretation method for tau-PET with 18F-flortaucipir. Alzheimers Dement (Amst). 2020;12:e12133.","journal-title":"Alzheimers Dement (Amst)."},{"key":"3081_CR56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","volume":"79","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, et al. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurol. 2022;79:149\u201358.","journal-title":"JAMA Neurol"},{"key":"3081_CR57","doi-asserted-by":"crossref","unstructured":"Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer\u2019s and Non-Alzheimer\u2019s Disease Tauopathies. Neuron. 2021;109.","DOI":"10.1016\/j.neuron.2020.09.042"},{"key":"3081_CR58","doi-asserted-by":"crossref","unstructured":"Mohammadi Z, Alizadeh H, Marton J, Cumming P The Sensitivity of Tau Tracers for the Discrimination of Alzheimer\u2019s Disease Patients and Healthy Controls by PET. Biomolecules. 2023;13.","DOI":"10.3390\/biom13020290"},{"key":"3081_CR59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/jlcr.3425","volume":"59","author":"DP Holt","year":"2016","unstructured":"Holt DP, Ravert HT, Dannals RF. Synthesis and quality control of [(18) F]T807 for tau PET imaging. J Labelled Comp Radiopharm. 2016;59:411\u201315.","journal-title":"J Labelled Comp Radiopharm"},{"key":"3081_CR60","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1016\/j.bmcl.2015.08.053","volume":"25","author":"M Wang","year":"2015","unstructured":"Wang M, Gao M, Xu Z, Zheng Q-H. Synthesis of a PET tau tracer [(11)C]PBB3 for imaging of Alzheimer\u2019s disease. Bioorg Med Chem Lett. 2015;25:4587\u201392.","journal-title":"Bioorg Med Chem Lett"},{"key":"3081_CR61","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2967\/jnumed.117.197426","volume":"59","author":"R Harada","year":"2018","unstructured":"Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, et al. Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease. J Nucl Med. 2018;59:671\u201374.","journal-title":"J Nucl Med"},{"key":"3081_CR62","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.27271","volume":"33","author":"C Vermeiren","year":"2018","unstructured":"Vermeiren C, Motte P, Viot D, Mairet-Coello G, Courade J-P, Citron M, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018;33:273\u201381.","journal-title":"Mov Disord"},{"key":"3081_CR63","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1007\/s00259-020-05156-4","volume":"48","author":"GN Bischof","year":"2021","unstructured":"Bischof GN, Dodich A, Boccardi M, van Eimeren T, Festari C, Barthel H, et al. Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48:2110\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3081_CR64","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurol. 2020;77:955\u201365.","journal-title":"JAMA Neurol"},{"key":"3081_CR65","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1093\/brain\/awaa180","volume":"143","author":"TA Pascoal","year":"2020","unstructured":"Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143:2818\u201330.","journal-title":"Brain."},{"key":"3081_CR66","volume":"19","author":"Y Li","year":"2019","unstructured":"Li Y, Yao Z, Yu Y, Zou Y, Fu Y, Hu B. Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography. BMC Psychiatry. 2019;19:165.","journal-title":"BMC Psychiatry"},{"key":"3081_CR67","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","volume":"217","author":"DV Hansen","year":"2018","unstructured":"Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer\u2019s disease. J Cell Biol. 2018;217:459\u201372.","journal-title":"J Cell Biol"},{"key":"3081_CR68","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/cns.12861","volume":"24","author":"Z-W Zhao","year":"2018","unstructured":"Zhao Z-W, Yuan Z, Zhao D-Q, Wang Z-W, Zhu F-Q, Luan P. The effect of V-ATPase function defects in pathogenesis of Alzheimer\u2019s disease. CNS Neurosci Ther. 2018;24:837\u201340.","journal-title":"CNS Neurosci Ther"},{"key":"3081_CR69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13024-022-00535-x","volume":"17","author":"A Sudwarts","year":"2022","unstructured":"Sudwarts A, Ramesha S, Gao T, Ponnusamy M, Wang S, Hansen M, et al. BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia. Mol Neurodegener. 2022;17:33.","journal-title":"Mol Neurodegener"},{"key":"3081_CR70","doi-asserted-by":"crossref","unstructured":"Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, et al. The Major Risk Factors for Alzheimer\u2019s Disease: Age, Sex, and Genes Modulate the Microglia Response to A\u03b2 Plaques. Cell Rep. 2019;27.","DOI":"10.1016\/j.celrep.2019.03.099"},{"key":"3081_CR71","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S2215-0366(20)30255-8","volume":"7","author":"JH Meyer","year":"2020","unstructured":"Meyer JH, Cervenka S, Kim M-J, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry. 2020;7:1064\u201374.","journal-title":"Lancet Psychiatry"},{"key":"3081_CR72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17:157\u201372.","journal-title":"Nat Rev Neurol"},{"key":"3081_CR73","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(01)05625-2","volume":"358","author":"A Cagnin","year":"2001","unstructured":"Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461\u201367.","journal-title":"Lancet"},{"key":"3081_CR74","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00259-010-1612-0","volume":"38","author":"M Yokokura","year":"2011","unstructured":"Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2011;38:343\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3081_CR75","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nrd3295","volume":"9","author":"R Rupprecht","year":"2010","unstructured":"Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9:971\u201388.","journal-title":"Nat Rev Drug Discov"},{"key":"3081_CR76","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2018.09.003","volume":"194","author":"TR Guilarte","year":"2019","unstructured":"Guilarte TR. TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward. Pharmacol Ther. 2019;194:44\u201358.","journal-title":"Pharmacol Ther"},{"key":"3081_CR77","doi-asserted-by":"crossref","unstructured":"Fan Z, Aman Y, Ahmed I, Chetelat G, Landeau B, Ray Chaudhuri K, et al. Influence of microglial activation on neuronal function in Alzheimer\u2019s and Parkinson\u2019s disease dementia. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2015;11.","DOI":"10.1016\/j.jalz.2014.06.016"},{"key":"3081_CR78","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00259-008-0908-9","volume":"35","author":"F Chauveau","year":"2008","unstructured":"Chauveau F, Boutin H, Van Camp N, Doll\u00e9 F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35:2304\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3081_CR79","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/0271678X16646788","volume":"37","author":"M Yokokura","year":"2017","unstructured":"Yokokura M, Terada T, Bunai T, Nakaizumi K, Takebayashi K, Iwata Y, et al. Depiction of microglial activation in aging and dementia: Positron emission tomography with [11C]DPA713 versus [11C](R)PK11195. J Cereb Blood Flow Metab. 2017;37:877\u201389.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3081_CR80","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2967\/jnumed.121.263004","volume":"63","author":"C Barca","year":"2022","unstructured":"Barca C, Kiliaan AJ, Wachsmuth L, Foray C, Hermann S, Faber C, et al. Short-Term Colony-Stimulating Factor 1 Receptor Inhibition-Induced Repopulation After Stroke Assessed by Longitudinal 18F-DPA-714 PET Imaging. J Nucl Med. 2022;63:1408\u201314.","journal-title":"J Nucl Med"},{"key":"3081_CR81","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2967\/jnumed.115.169078","volume":"57","author":"Z Fan","year":"2016","unstructured":"Fan Z, Calsolaro V, Atkinson RA, Femminella GD, Waldman A, Buckley C, et al. Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. J Nucl Med. 2016;57:1753\u201359.","journal-title":"J Nucl Med"},{"key":"3081_CR82","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1038\/s41596-021-00584-4","volume":"16","author":"J Hong","year":"2021","unstructured":"Hong J, Telu S, Zhang Y, Miller WH, Shetty HU, Morse CL, et al. Translation of 11C-labeled tracer synthesis to a CGMP environment as exemplified by [11C]ER176 for PET imaging of human TSPO. Nat Protoc. 2021;16:4419\u201345.","journal-title":"Nat Protoc"},{"key":"3081_CR83","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.2967\/jnumed.121.263200","volume":"63","author":"JC Masdeu","year":"2022","unstructured":"Masdeu JC, Pascual B, Fujita M. Imaging Neuroinflammation in Neurodegenerative Disorders. J Nucl Med. 2022;63:45S\u201352S.","journal-title":"J Nucl Med"},{"key":"3081_CR84","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0306-4522(94)90311-5","volume":"62","author":"J Saura","year":"1994","unstructured":"Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 1994;62:15\u201330.","journal-title":"Neuroscience"},{"key":"3081_CR85","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/jcbfm.2014.34","volume":"34","author":"PM Rusjan","year":"2014","unstructured":"Rusjan PM, Wilson AA, Miler L, Fan I, Mizrahi R, Houle S, et al. Kinetic modeling of the monoamine oxidase B radioligand [\u00b9\u00b9C]SL25.1188 in human brain with high-resolution positron emission tomography. J Cereb Blood Flow Metab. 2014;34:883\u201389.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3081_CR86","doi-asserted-by":"crossref","unstructured":"Parker CA, Nutt DJ, Tyacke RJ Imidazoline-I2 PET Tracers in Neuroimaging. Int J Mol Sci. 2023;24.","DOI":"10.3390\/ijms24129787"},{"key":"3081_CR87","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2967\/jnumed.118.208009","volume":"59","author":"RJ Tyacke","year":"2018","unstructured":"Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, et al. Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Site in Human Brain. J Nucl Med. 2018;59:1597\u2013602.","journal-title":"J Nucl Med"},{"key":"3081_CR88","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1038\/s41380-021-01193-z","volume":"26","author":"V Calsolaro","year":"2021","unstructured":"Calsolaro V, Matthews PM, Donat CK, Livingston NR, Femminella GD, Guedes SS, et al. Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load. Mol Psychiatry. 2021;26:5848\u201355.","journal-title":"Mol Psychiatry"},{"key":"3081_CR89","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1073\/pnas.1812155116","volume":"116","author":"AG Horti","year":"2019","unstructured":"Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci USA. 2019;116:1686\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3081_CR90","volume":"8","author":"B Janssen","year":"2018","unstructured":"Janssen B, Vugts DJ, Wilkinson SM, Ory D, Chalon S, Hoozemans JJM, et al. Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. Sci Rep. 2018;8:6580.","journal-title":"Sci Rep"},{"key":"3081_CR91","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.mad.2005.09.016","volume":"127","author":"A Lanari","year":"2006","unstructured":"Lanari A, Amenta F, Silvestrelli G, Tomassoni D, Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer\u2019s disease. Mech Ageing Dev. 2006;127:158\u201365.","journal-title":"Mech Ageing Dev"},{"key":"3081_CR92","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11920-005-0019-2","volume":"7","author":"GC Rom\u00e1n","year":"2005","unstructured":"Rom\u00e1n GC. Cholinergic dysfunction in vascular dementia. Curr Psychiatry Rep. 2005;7:18\u201326.","journal-title":"Curr Psychiatry Rep"},{"key":"3081_CR93","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3233\/JPD-223489","volume":"12","author":"J Horsager","year":"2022","unstructured":"Horsager J, Okkels N, Hansen AK, Damholdt MF, Andersen KH, Fedorova TD, et al. Mapping Cholinergic Synaptic Loss in Parkinson\u2019s Disease: An [18F]FEOBV PET Case-Control Study. J Parkinsons Dis. 2022;12:2493\u2013506.","journal-title":"J Parkinsons Dis"},{"key":"3081_CR94","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/jnr.490270419","volume":"27","author":"KJ Reinikainen","year":"1990","unstructured":"Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer\u2019s disease: implications to diagnostics and therapy. J Neurosci Res. 1990;27:576\u201386.","journal-title":"J Neurosci Res"},{"key":"3081_CR95","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141:1917\u201333.","journal-title":"Brain"},{"key":"3081_CR96","volume":"14","author":"W Li","year":"2022","unstructured":"Li W, Wang Y, Lohith TG, Zeng Z, Tong L, Mazzola R, et al. The PET tracer [11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer\u2019s disease. Sci Transl Med. 2022;14:eabg3684.","journal-title":"Sci Transl Med"},{"key":"3081_CR97","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2967\/jnumed.119.230979","volume":"61","author":"JM Coughlin","year":"2020","unstructured":"Coughlin JM, Rubin LH, Du Y, Rowe SP, Crawford JL, Rosenthal HB, et al. High Availability of the \u03b17-Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using 18F-ASEM PET. J Nucl Med. 2020;61:423\u201326.","journal-title":"J Nucl Med"},{"key":"3081_CR98","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3233\/JAD-2012-111748","volume":"31","author":"A Marcone","year":"2012","unstructured":"Marcone A, Garibotto V, Moresco RM, Florea I, Panzacchi A, Carpinelli A, et al. 11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer\u2019s disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis. J Alzheimers Dis. 2012;31:387\u201399.","journal-title":"J Alzheimers Dis"},{"key":"3081_CR99","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pneurobio.2016.04.001","volume":"151","author":"G \u0160imi\u0107","year":"2017","unstructured":"\u0160imi\u0107 G, Babi\u0107 Leko M, Wray S, Harrington CR, Delalle I, Jovanov-Milo\u0161evi\u0107 N, et al. Monoaminergic neuropathology in Alzheimer\u2019s disease. Prog Neurobiol. 2017;151:101\u201338.","journal-title":"Prog Neurobiol"},{"key":"3081_CR100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nbd.2012.06.001","volume":"52","author":"JB Savitz","year":"2013","unstructured":"Savitz JB, Drevets WC. Neuroreceptor imaging in depression. Neurobiol Dis. 2013;52:49\u201365.","journal-title":"Neurobiol Dis"},{"key":"3081_CR101","doi-asserted-by":"crossref","unstructured":"Yanai K, Tashiro M The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther. 2007;113.","DOI":"10.1016\/j.pharmthera.2006.06.008"},{"key":"3081_CR102","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2967\/jnumed.111.088005","volume":"52","author":"S Paul","year":"2011","unstructured":"Paul S, Khanapur S, Rybczynska AA, Kwizera C, Sijbesma JWA, Ishiwata K, et al. Small-animal PET study of adenosine A(1) receptors in rat brain: blocking receptors and raising extracellular adenosine. J Nucl Med. 2011;52:1293\u2013300.","journal-title":"J Nucl Med"},{"key":"3081_CR103","first-page":"3831","volume":"12","author":"Y-S Ding","year":"2006","unstructured":"Ding Y-S, Lin K-S, Logan J. PET imaging of norepinephrine transporters. Curr Pharm Des. 2006;12:3831\u201345.","journal-title":"Curr Pharm Des"},{"key":"3081_CR104","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.semcdb.2022.03.013","volume":"139","author":"B Zott","year":"2023","unstructured":"Zott B, Konnerth A. Impairments of glutamatergic synaptic transmission in Alzheimer\u2019s disease. Semin Cell Dev Biol. 2023;139:24\u201334.","journal-title":"Semin Cell Dev Biol"},{"key":"3081_CR105","doi-asserted-by":"crossref","DOI":"10.1186\/s13041-015-0107-0","volume":"8","author":"A Hamilton","year":"2015","unstructured":"Hamilton A, Zamponi GW, Ferguson SSG. Glutamate receptors function as scaffolds for the regulation of \u03b2-amyloid and cellular prion protein signaling complexes. Mol Brain. 2015;8:18.","journal-title":"Mol Brain"},{"key":"3081_CR106","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/acs.jmedchem.8b00714","volume":"62","author":"H Fu","year":"2019","unstructured":"Fu H, Chen Z, Josephson L, Li Z, Liang SH. Positron Emission Tomography (PET) Ligand Development for Ionotropic Glutamate Receptors: Challenges and Opportunities for Radiotracer Targeting N-Methyl-d-aspartate (NMDA), \u03b1-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA), and Kainate Receptors. J Med Chem. 2019;62:403\u201319.","journal-title":"J Med Chem"},{"key":"3081_CR107","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/716514","volume":"2015","author":"T Fuchigami","year":"2015","unstructured":"Fuchigami T, Nakayama M, Yoshida S. Development of PET and SPECT probes for glutamate receptors. ScientificWorldJournal. 2015;2015:716514.","journal-title":"ScientificWorldJournal"},{"key":"3081_CR108","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1755-5949.2012.00365.x","volume":"18","author":"P Luan","year":"2012","unstructured":"Luan P, Zhou H-H, Zhang B, Liu A-M, Yang L-H, Weng X-L, et al. Basic fibroblast growth factor protects C17.2 cells from radiation-induced injury through ERK1\/2. CNS Neurosci Ther. 2012;18:767\u201372.","journal-title":"CNS Neurosci Ther"},{"key":"3081_CR109","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cns.12044","volume":"19","author":"Z-Y Zhao","year":"2013","unstructured":"Zhao Z-Y, Luan P, Huang S-X, Xiao S-H, Zhao J, Zhang B, et al. Edaravone protects HT22 neurons from H2O2-induced apoptosis by inhibiting the MAPK signaling pathway. CNS Neurosci Ther. 2013;19:163\u201369.","journal-title":"CNS Neurosci Ther"},{"key":"3081_CR110","volume":"19","author":"CV Rao","year":"2020","unstructured":"Rao CV, Farooqui M, Madhavaram A, Zhang Y, Asch AS, Yamada HY. GSK3-ARC\/Arg3.1 and GSK3-Wnt signaling axes trigger amyloid-\u03b2 accumulation and neuroinflammation in middle-aged Shugoshin 1 mice. Aging Cell. 2020;19:e13221.","journal-title":"Aging Cell"},{"key":"3081_CR111","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1523\/JNEUROSCI.0889-12.2012","volume":"32","author":"DE Hurtado","year":"2012","unstructured":"Hurtado DE, Molina-Porcel L, Carroll JC, Macdonald C, Aboagye AK, Trojanowski JQ, et al. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer\u2019s disease. J Neurosci. 2012;32:7392\u2013402.","journal-title":"J Neurosci"},{"key":"3081_CR112","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1021\/acschemneuro.6b00376","volume":"8","author":"J Prabhakaran","year":"2017","unstructured":"Prabhakaran J, Zanderigo F, Sai KKS, Rubin-Falcone H, Jorgensen MJ, Kaplan JR, et al. Radiosynthesis and in Vivo Evaluation of [11C]A1070722, a High Affinity GSK-3 PET Tracer in Primate Brain. ACS Chem Neurosci. 2017;8:1697\u2013703.","journal-title":"ACS Chem Neurosci"},{"key":"3081_CR113","doi-asserted-by":"crossref","first-page":"22959","DOI":"10.1016\/S0021-9258(19)49409-X","volume":"268","author":"AY Hung","year":"1993","unstructured":"Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, et al. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem. 1993;268:22959\u201362.","journal-title":"J Biol Chem"},{"key":"3081_CR114","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.exger.2009.10.015","volume":"45","author":"J de Barry","year":"2010","unstructured":"de Barry J, Li\u00e9geois CM, Janoshazi A. Protein kinase C as a peripheral biomarker for Alzheimer\u2019s disease. Exp Gerontol. 2010;45:64\u201369.","journal-title":"Exp Gerontol"},{"key":"3081_CR115","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.bmcl.2011.01.100","volume":"21","author":"M Wang","year":"2011","unstructured":"Wang M, Xu L, Gao M, Miller KD, Sledge GW, Zheng Q-H. 11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C. Bioorg Med Chem Lett. 2011;21:1649\u201353.","journal-title":"Bioorg Med Chem Lett"},{"key":"3081_CR116","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1021\/bi7000032","volume":"46","author":"C Ha","year":"2007","unstructured":"Ha C, Ryu J, Park CB. Metal ions differentially influence the aggregation and deposition of Alzheimer\u2019s beta-amyloid on a solid template. Biochemistry. 2007;46:6118\u201325.","journal-title":"Biochemistry"},{"key":"3081_CR117","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acschemneuro.5b00055","volume":"6","author":"SH Liang","year":"2015","unstructured":"Liang SH, Holland JP, Stephenson NA, Kassenbrock A, Rotstein BH, Daignault CP, et al. PET neuroimaging studies of [(18)F]CABS13 in a double transgenic mouse model of Alzheimer\u2019s disease and nonhuman primates. ACS Chem Neurosci. 2015;6:535\u201341.","journal-title":"ACS Chem Neurosci"},{"key":"3081_CR118","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/s41380-022-01565-z","volume":"27","author":"L Peng","year":"2022","unstructured":"Peng L, Bestard-Lorigados I, Song W. The synapse as a treatment avenue for Alzheimer\u2019s Disease. Mol Psychiatry. 2022;27:2940\u201349.","journal-title":"Mol Psychiatry"},{"key":"3081_CR119","first-page":"E2895","volume":"109","author":"PE Sanchez","year":"2012","unstructured":"Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer\u2019s disease model. Proc Natl Acad Sci USA. 2012;109:E2895\u2013E903.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3081_CR120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11307-018-1260-5","volume":"21","author":"CC Constantinescu","year":"2019","unstructured":"Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, et al. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers. Mol Imaging Biol. 2019;21:509\u201318.","journal-title":"Mol Imaging Biol"},{"key":"3081_CR121","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1002\/alz.12582","volume":"18","author":"AP Mecca","year":"2022","unstructured":"Mecca AP, O\u2019Dell RS, Sharp ES, Banks ER, Bartlett HH, Zhao W, et al. Synaptic density and cognitive performance in Alzheimer\u2019s disease: A PET imaging study with [11 C]UCB-J. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2022;18:2527\u201336.","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association."},{"key":"3081_CR122","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1021\/acschemneuro.9b00618","volume":"11","author":"Z Cai","year":"2020","unstructured":"Cai Z, Li S, Zhang W, Pracitto R, Wu X, Baum E, et al. Synthesis and Preclinical Evaluation of an 18F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT-2. ACS Chem Neurosci. 2020;11:592\u2013603.","journal-title":"ACS Chem Neurosci"},{"key":"3081_CR123","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1042\/BST20130140","volume":"41","author":"N Maroof","year":"2013","unstructured":"Maroof N, Pardon MC, Kendall DA. Endocannabinoid signalling in Alzheimer\u2019s disease. Biochem Soc Trans. 2013;41:1583\u201387.","journal-title":"Biochem Soc Trans"},{"key":"3081_CR124","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1021\/acschemneuro.0c00313","volume":"11","author":"S Lahdenpohja","year":"2020","unstructured":"Lahdenpohja S, Rajala NA, Helin JS, Haaparanta-Solin M, Solin O, L\u00f3pez-Pic\u00f3n FR, et al. Ruthenium-Mediated 18F-Fluorination and Preclinical Evaluation of a New CB1 Receptor Imaging Agent [18F]FPATPP. ACS Chem Neurosci. 2020;11:2009\u201318.","journal-title":"ACS Chem Neurosci"},{"key":"3081_CR125","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1021\/acs.jmedchem.7b00155","volume":"60","author":"F Spinelli","year":"2017","unstructured":"Spinelli F, Capparelli E, Abate C, Colabufo NA, Contino M. Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies. J Med Chem. 2017;60:9913\u201331.","journal-title":"J Med Chem"},{"key":"3081_CR126","volume":"30","author":"Z Chen","year":"2020","unstructured":"Chen Z, Hou L, Gan J, Cai Q, Ye W, Chen J, et al. Synthesis and preliminary evaluation of a novel positron emission tomography (PET) ligand for imaging fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett. 2020;30:127513.","journal-title":"Bioorg Med Chem Lett"},{"key":"3081_CR127","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10571-015-0233-3","volume":"36","author":"Z Cai","year":"2016","unstructured":"Cai Z, Liu N, Wang C, Qin B, Zhou Y, Xiao M, et al. Role of RAGE in Alzheimer\u2019s Disease. Cell Mol Neurobiol. 2016;36:483\u201395.","journal-title":"Cell Mol Neurobiol"},{"key":"3081_CR128","doi-asserted-by":"crossref","unstructured":"Paudel YN, Angelopoulou E, Piperi C, Othman I, Aamir K, Shaikh MF Impact of HMGB1, RAGE, and TLR4 in Alzheimer\u2019s Disease (AD): From Risk Factors to Therapeutic Targeting. Cells. 2020;9.","DOI":"10.3390\/cells9020383"},{"key":"3081_CR129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrd3727","volume":"11","author":"S Crunkhorn","year":"2012","unstructured":"Crunkhorn S. Neurodegenerative disease: Taming the RAGE of Alzheimer\u2019s disease. Nat Rev Drug Discov. 2012;11:351.","journal-title":"Nat Rev Drug Discov"},{"key":"3081_CR130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1021\/acschemneuro.5b00319","volume":"7","author":"BP Cary","year":"2016","unstructured":"Cary BP, Brooks AF, Fawaz MV, Drake LR, Desmond TJ, Sherman P, et al. Synthesis and Evaluation of [(18)F]RAGER: A First Generation Small-Molecule PET Radioligand Targeting the Receptor for Advanced Glycation Endproducts. ACS Chem Neurosci. 2016;7:391\u201398.","journal-title":"ACS Chem Neurosci"},{"key":"3081_CR131","doi-asserted-by":"crossref","unstructured":"Chai AB, Callaghan R, Gelissen IC Regulation of P-Glycoprotein in the Brain. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms232314667"},{"key":"3081_CR132","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2967\/jnumed.113.130161","volume":"55","author":"AK Deo","year":"2014","unstructured":"Deo AK, Borson S, Link JM, Domino K, Eary JF, Ke B, et al. Activity of P-Glycoprotein, a \u03b2-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. J Nucl Med. 2014;55:1106\u201311.","journal-title":"J Nucl Med"},{"key":"3081_CR133","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1021\/cn3001729","volume":"4","author":"S Syv\u00e4nen","year":"2013","unstructured":"Syv\u00e4nen S, Eriksson J. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem Neurosci. 2013;4:225\u201337.","journal-title":"ACS Chem Neurosci"},{"key":"3081_CR134","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2967\/jnumed.107.047308","volume":"49","author":"SS Zoghbi","year":"2008","unstructured":"Zoghbi SS, Liow J-S, Yasuno F, Hong J, Tuan E, Lazarova N, et al. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med. 2008;49:649\u201356.","journal-title":"J Nucl Med"},{"key":"3081_CR135","first-page":"493","volume":"41","author":"A Levchenko","year":"2000","unstructured":"Levchenko A, Mehta BM, Lee JB, Humm JL, Augensen F, Squire O, et al. Evaluation of 11C-colchicine for PET imaging of multiple drug resistance. J Nucl Med. 2000;41:493\u2013501.","journal-title":"J Nucl Med"},{"key":"3081_CR136","doi-asserted-by":"crossref","DOI":"10.1186\/2191-219X-2-12","volume":"2","author":"FE Froklage","year":"2012","unstructured":"Froklage FE, Syv\u00e4nen S, Hendrikse NH, Huisman MC, Molthoff CF, Tagawa Y, et al. [11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein. EJNMMI Res. 2012;2:12.","journal-title":"EJNMMI Res"},{"key":"3081_CR137","first-page":"1330","volume":"44","author":"KA Kurdziel","year":"2003","unstructured":"Kurdziel KA, Kiesewetter DO, Carson RE, Eckelman WC, Herscovitch P. Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J Nucl Med. 2003;44:1330\u201339.","journal-title":"J Nucl Med"},{"key":"3081_CR138","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3233\/JAD-200890","volume":"79","author":"Y-W Bao","year":"2021","unstructured":"Bao Y-W, Chau ACM, Chiu PK-C, Shea YF, Kwan JSK, Chan FHW, et al. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer\u2019s Disease and Other Dementias. J Alzheimers Dis. 2021;79:819\u201332.","journal-title":"J Alzheimers Dis"},{"key":"3081_CR139","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/RLU.0000000000003471","volume":"46","author":"S Lee","year":"2021","unstructured":"Lee S, Jung JH, Kim D, Lim HK, Park M-A, Kim G, et al. PET\/CT for Brain Amyloid: A Feasibility Study for Scan Time Reduction by Deep Learning. Clin Nucl Med. 2021;46:e133\u2013e40.","journal-title":"Clin Nucl Med"},{"key":"3081_CR140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fnmol.2017.00343","volume":"10","author":"XY Zhang","year":"2017","unstructured":"Zhang XY, Yang ZL, Lu GM, Yang GF, Zhang LJ. PET\/MR Imaging: New Frontier in Alzheimer\u2019s Disease and Other Dementias. Front Mol Neurosci. 2017;10:343.","journal-title":"Front Mol Neurosci"},{"key":"3081_CR141","doi-asserted-by":"crossref","DOI":"10.1002\/alz.13158","volume":"19","author":"A Bollack","year":"2023","unstructured":"Bollack A, Collij LE, Garc\u00eda DV, Shekari M, Altomare D, Payoux P, et al. A Centiloid cut-off to help predict true amyloid accumulation. Alzheimer\u2019s & Dementia. 2023;19:e074619.","journal-title":"Alzheimer\u2019s & Dementia."},{"key":"3081_CR142","doi-asserted-by":"crossref","DOI":"10.1002\/alz.12876","volume":"19","author":"I Gueorguieva","year":"2023","unstructured":"Gueorguieva I, Chua L, Chow KH, Ernest CS, Willis BA, Shcherbinin S, et al. Donanemab exposure-efficacy relationship in patients with early symptomatic Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2023;19:e062599.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"3081_CR143","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019;321:1286\u201394.","journal-title":"JAMA"},{"key":"3081_CR144","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14321","volume":"21","author":"MW Weiner","year":"2025","unstructured":"Weiner MW, Kanoria S, Miller MJ, Aisen PS, Beckett LA, Conti C, et al. Overview of Alzheimer\u2019s Disease Neuroimaging Initiative and future clinical trials. Alzheimer\u2019s & Dementia. 2025;21:e14321.","journal-title":"Alzheimer\u2019s & Dementia"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03081-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03081-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03081-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T15:43:51Z","timestamp":1757951031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03081-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":144,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3081"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03081-2","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}